Concepts (199)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Toxoplasmosis, Congenital | 19 | 2015 | 26 | 1.890 |
Why?
|
| Toxoplasma | 12 | 2017 | 18 | 1.210 |
Why?
|
| Antibiotic Prophylaxis | 3 | 2016 | 36 | 0.770 |
Why?
|
| Toxoplasmosis | 5 | 2017 | 10 | 0.690 |
Why?
|
| Cesarean Section | 1 | 2016 | 30 | 0.580 |
Why?
|
| Pregnancy | 14 | 2016 | 403 | 0.560 |
Why?
|
| Streptococcal Infections | 4 | 1998 | 14 | 0.540 |
Why?
|
| Streptococcus agalactiae | 4 | 1998 | 8 | 0.480 |
Why?
|
| Antibodies, Protozoan | 6 | 2017 | 12 | 0.440 |
Why?
|
| Food Contamination | 1 | 2011 | 4 | 0.420 |
Why?
|
| Infant, Newborn | 19 | 2015 | 604 | 0.410 |
Why?
|
| Eating | 1 | 2011 | 45 | 0.400 |
Why?
|
| Toxoplasmosis, Ocular | 6 | 2008 | 7 | 0.400 |
Why?
|
| Pregnancy Complications, Parasitic | 6 | 2011 | 7 | 0.390 |
Why?
|
| Pregnancy Complications, Infectious | 3 | 1998 | 30 | 0.330 |
Why?
|
| Antiprotozoal Agents | 5 | 2008 | 11 | 0.330 |
Why?
|
| Infant | 15 | 2020 | 531 | 0.270 |
Why?
|
| Prenatal Diagnosis | 2 | 2005 | 15 | 0.270 |
Why?
|
| Measles Vaccine | 1 | 2005 | 2 | 0.270 |
Why?
|
| Measles | 1 | 2005 | 2 | 0.270 |
Why?
|
| Immunoassay | 2 | 2017 | 41 | 0.260 |
Why?
|
| Humans | 37 | 2020 | 29337 | 0.230 |
Why?
|
| Sulfadiazine | 10 | 2008 | 11 | 0.220 |
Why?
|
| Female | 21 | 2016 | 16197 | 0.210 |
Why?
|
| Infectious Disease Transmission, Vertical | 3 | 2000 | 19 | 0.200 |
Why?
|
| Immunoglobulin G | 3 | 2017 | 129 | 0.200 |
Why?
|
| Phenotype | 2 | 2020 | 355 | 0.190 |
Why?
|
| Pyrimethamine | 11 | 2008 | 13 | 0.190 |
Why?
|
| Myeloproliferative Disorders | 1 | 2020 | 4 | 0.190 |
Why?
|
| Noonan Syndrome | 1 | 2020 | 2 | 0.190 |
Why?
|
| Immunoglobulin M | 2 | 2017 | 19 | 0.190 |
Why?
|
| ras Proteins | 1 | 2020 | 11 | 0.190 |
Why?
|
| Tachycardia, Ventricular | 1 | 2020 | 34 | 0.180 |
Why?
|
| Anti-Bacterial Agents | 2 | 2016 | 402 | 0.180 |
Why?
|
| Chorioretinitis | 2 | 2008 | 3 | 0.160 |
Why?
|
| Point-of-Care Testing | 1 | 2017 | 24 | 0.150 |
Why?
|
| Hydrocephalus | 2 | 2015 | 25 | 0.140 |
Why?
|
| Genotype | 2 | 2015 | 405 | 0.140 |
Why?
|
| Child, Preschool | 9 | 2015 | 642 | 0.140 |
Why?
|
| Cluster Analysis | 1 | 2015 | 52 | 0.140 |
Why?
|
| Family Health | 1 | 2015 | 37 | 0.140 |
Why?
|
| Child | 10 | 2015 | 1346 | 0.140 |
Why?
|
| Fathers | 1 | 2015 | 22 | 0.130 |
Why?
|
| Surgical Wound Infection | 1 | 2016 | 97 | 0.130 |
Why?
|
| Adult | 9 | 2011 | 8601 | 0.120 |
Why?
|
| Polymerase Chain Reaction | 2 | 2005 | 161 | 0.110 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2015 | 130 | 0.110 |
Why?
|
| Antigens, Protozoan | 2 | 2011 | 4 | 0.110 |
Why?
|
| Oocysts | 1 | 2011 | 3 | 0.110 |
Why?
|
| North America | 1 | 2011 | 38 | 0.100 |
Why?
|
| Drug Therapy, Combination | 5 | 2008 | 241 | 0.100 |
Why?
|
| Cohort Studies | 4 | 2015 | 1939 | 0.100 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2011 | 34 | 0.100 |
Why?
|
| Protozoan Proteins | 1 | 2011 | 2 | 0.100 |
Why?
|
| Male | 12 | 2020 | 15621 | 0.090 |
Why?
|
| Adolescent | 6 | 2015 | 2279 | 0.090 |
Why?
|
| Leucovorin | 7 | 2008 | 16 | 0.090 |
Why?
|
| Risk Factors | 4 | 2005 | 2443 | 0.090 |
Why?
|
| Animals | 9 | 2011 | 4552 | 0.080 |
Why?
|
| Retinal Hemorrhage | 1 | 2008 | 2 | 0.080 |
Why?
|
| Choroidal Neovascularization | 1 | 2008 | 2 | 0.080 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2008 | 17 | 0.080 |
Why?
|
| Collagen Type II | 1 | 2008 | 31 | 0.080 |
Why?
|
| Eosinophilia | 2 | 2006 | 47 | 0.080 |
Why?
|
| Vision Disorders | 2 | 2006 | 23 | 0.080 |
Why?
|
| Cataract | 1 | 2007 | 20 | 0.080 |
Why?
|
| Epigenesis, Genetic | 1 | 2008 | 74 | 0.080 |
Why?
|
| Retinal Diseases | 1 | 2007 | 8 | 0.080 |
Why?
|
| Incidence | 4 | 2015 | 756 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 1 | 2008 | 260 | 0.080 |
Why?
|
| Sepsis | 1 | 1988 | 144 | 0.070 |
Why?
|
| Drug Hypersensitivity | 1 | 2006 | 17 | 0.070 |
Why?
|
| Larva Migrans, Visceral | 1 | 1985 | 1 | 0.070 |
Why?
|
| Nematode Infections | 1 | 1985 | 1 | 0.070 |
Why?
|
| Raccoons | 1 | 1985 | 1 | 0.070 |
Why?
|
| Meningoencephalitis | 1 | 1985 | 5 | 0.070 |
Why?
|
| Practice Guidelines as Topic | 2 | 1998 | 333 | 0.070 |
Why?
|
| Morbillivirus | 1 | 2005 | 1 | 0.070 |
Why?
|
| Visual Acuity | 3 | 2008 | 42 | 0.060 |
Why?
|
| Prevalence | 2 | 2015 | 487 | 0.050 |
Why?
|
| United States | 3 | 2017 | 2333 | 0.050 |
Why?
|
| Brain | 4 | 2011 | 1689 | 0.050 |
Why?
|
| Heterozygote | 1 | 2020 | 103 | 0.040 |
Why?
|
| Recurrence | 3 | 2007 | 350 | 0.040 |
Why?
|
| Chicago | 3 | 2015 | 865 | 0.040 |
Why?
|
| Toxoplasmosis, Cerebral | 2 | 1996 | 3 | 0.040 |
Why?
|
| Cognition Disorders | 1 | 2006 | 1011 | 0.040 |
Why?
|
| Calcinosis | 2 | 1996 | 47 | 0.040 |
Why?
|
| Mutation | 1 | 2020 | 383 | 0.040 |
Why?
|
| Wiskott-Aldrich Syndrome | 1 | 1997 | 1 | 0.040 |
Why?
|
| Keratitis, Herpetic | 1 | 1997 | 1 | 0.040 |
Why?
|
| Herpesvirus 1, Human | 1 | 1997 | 2 | 0.040 |
Why?
|
| Acyclovir | 1 | 1997 | 5 | 0.040 |
Why?
|
| Prospective Studies | 3 | 2008 | 1811 | 0.040 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2017 | 16 | 0.040 |
Why?
|
| Developing Countries | 1 | 2017 | 22 | 0.040 |
Why?
|
| Costs and Cost Analysis | 1 | 2017 | 36 | 0.040 |
Why?
|
| Lymphadenitis | 1 | 1996 | 2 | 0.040 |
Why?
|
| Fertilization | 1 | 1996 | 5 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 1997 | 144 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 1997 | 132 | 0.040 |
Why?
|
| Longitudinal Studies | 3 | 2008 | 1442 | 0.040 |
Why?
|
| Algorithms | 1 | 1998 | 400 | 0.030 |
Why?
|
| Agglutination Tests | 1 | 2015 | 4 | 0.030 |
Why?
|
| Serogroup | 1 | 2015 | 3 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 553 | 0.030 |
Why?
|
| Tetanus Toxoid | 1 | 1995 | 10 | 0.030 |
Why?
|
| Fetal Diseases | 1 | 1995 | 6 | 0.030 |
Why?
|
| Intelligence | 1 | 1995 | 25 | 0.030 |
Why?
|
| Vaccination | 1 | 1995 | 41 | 0.030 |
Why?
|
| Treatment Outcome | 4 | 2008 | 3478 | 0.030 |
Why?
|
| Serotyping | 1 | 2012 | 12 | 0.030 |
Why?
|
| Virulence | 1 | 2012 | 15 | 0.030 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 1992 | 16 | 0.030 |
Why?
|
| Alleles | 1 | 2012 | 224 | 0.030 |
Why?
|
| Meat | 1 | 2011 | 2 | 0.030 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2011 | 9 | 0.030 |
Why?
|
| Swine Diseases | 1 | 2011 | 6 | 0.030 |
Why?
|
| Swine | 1 | 2011 | 80 | 0.020 |
Why?
|
| Cats | 1 | 2011 | 76 | 0.020 |
Why?
|
| Drug Administration Schedule | 2 | 2006 | 223 | 0.020 |
Why?
|
| Mice | 2 | 2011 | 1607 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2011 | 170 | 0.020 |
Why?
|
| Feasibility Studies | 2 | 2006 | 227 | 0.020 |
Why?
|
| Cell Line | 1 | 2011 | 298 | 0.020 |
Why?
|
| Infant, Newborn, Diseases | 2 | 1996 | 17 | 0.020 |
Why?
|
| Lymphocytes | 1 | 1990 | 110 | 0.020 |
Why?
|
| Ranibizumab | 1 | 2008 | 2 | 0.020 |
Why?
|
| Fluorescein Angiography | 1 | 2008 | 11 | 0.020 |
Why?
|
| Vitreous Body | 1 | 2008 | 7 | 0.020 |
Why?
|
| Tomography, Optical Coherence | 1 | 2008 | 16 | 0.020 |
Why?
|
| Genomic Imprinting | 1 | 2008 | 2 | 0.020 |
Why?
|
| Injections | 1 | 2008 | 56 | 0.020 |
Why?
|
| Linkage Disequilibrium | 1 | 2008 | 47 | 0.020 |
Why?
|
| Eye | 1 | 2008 | 10 | 0.020 |
Why?
|
| Cataract Extraction | 1 | 2007 | 4 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2008 | 113 | 0.020 |
Why?
|
| Vision, Binocular | 1 | 2006 | 2 | 0.020 |
Why?
|
| Vision, Monocular | 1 | 2006 | 2 | 0.020 |
Why?
|
| Gram-Negative Bacteria | 1 | 1986 | 37 | 0.020 |
Why?
|
| Macula Lutea | 1 | 2006 | 7 | 0.020 |
Why?
|
| Wechsler Scales | 1 | 2006 | 14 | 0.020 |
Why?
|
| Intelligence Tests | 1 | 2006 | 15 | 0.020 |
Why?
|
| Pattern Recognition, Visual | 1 | 2006 | 31 | 0.020 |
Why?
|
| Language Tests | 1 | 2006 | 29 | 0.020 |
Why?
|
| Ascaridoidea | 1 | 1985 | 1 | 0.020 |
Why?
|
| Larva | 1 | 1985 | 3 | 0.020 |
Why?
|
| Infant, Premature | 1 | 1986 | 178 | 0.020 |
Why?
|
| Young Adult | 1 | 2011 | 1932 | 0.020 |
Why?
|
| Milk, Human | 1 | 1986 | 156 | 0.010 |
Why?
|
| Obstetrics and Gynecology Department, Hospital | 1 | 1983 | 3 | 0.010 |
Why?
|
| Hospital Departments | 1 | 1983 | 9 | 0.010 |
Why?
|
| Patient Isolation | 1 | 1983 | 23 | 0.010 |
Why?
|
| Patient Care Planning | 1 | 1983 | 56 | 0.010 |
Why?
|
| Pilot Projects | 2 | 1994 | 394 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2006 | 1113 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 2 | 1996 | 770 | 0.010 |
Why?
|
| Cross Infection | 1 | 1983 | 298 | 0.010 |
Why?
|
| Eye Diseases | 1 | 2000 | 7 | 0.010 |
Why?
|
| Follow-Up Studies | 2 | 1996 | 1830 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2000 | 389 | 0.010 |
Why?
|
| Cognition | 1 | 2006 | 1277 | 0.010 |
Why?
|
| Drug Resistance, Microbial | 1 | 1997 | 96 | 0.010 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 1996 | 9 | 0.010 |
Why?
|
| Immunocompetence | 1 | 1996 | 6 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 1996 | 70 | 0.010 |
Why?
|
| Anti-Infective Agents | 1 | 1996 | 63 | 0.010 |
Why?
|
| Psychological Tests | 1 | 1995 | 52 | 0.010 |
Why?
|
| Motor Skills | 1 | 1995 | 61 | 0.010 |
Why?
|
| Seizures | 1 | 1995 | 87 | 0.010 |
Why?
|
| Mothers | 1 | 1996 | 178 | 0.010 |
Why?
|
| Spiramycin | 1 | 1994 | 1 | 0.010 |
Why?
|
| Prenatal Care | 1 | 1994 | 8 | 0.010 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 1994 | 11 | 0.010 |
Why?
|
| Neutropenia | 1 | 1994 | 21 | 0.010 |
Why?
|
| Child Development | 1 | 1995 | 71 | 0.010 |
Why?
|
| Brain Diseases | 1 | 1994 | 82 | 0.010 |
Why?
|
| Physical Examination | 1 | 1994 | 117 | 0.010 |
Why?
|
| Nervous System Diseases | 1 | 1995 | 145 | 0.010 |
Why?
|
| Phenobarbital | 1 | 1992 | 5 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1992 | 36 | 0.010 |
Why?
|
| Audiometry, Evoked Response | 1 | 1992 | 1 | 0.010 |
Why?
|
| Time Factors | 1 | 1996 | 1616 | 0.010 |
Why?
|
| Concanavalin A | 1 | 1990 | 3 | 0.010 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 1990 | 8 | 0.010 |
Why?
|
| Interleukin-2 | 1 | 1990 | 66 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 1990 | 109 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 1990 | 209 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 1994 | 1221 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 1996 | 3273 | 0.000 |
Why?
|
| Peritoneum | 1 | 1986 | 18 | 0.000 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 1986 | 16 | 0.000 |
Why?
|
| Enteral Nutrition | 1 | 1986 | 49 | 0.000 |
Why?
|
| Risk | 1 | 1986 | 217 | 0.000 |
Why?
|
| Hospital Bed Capacity, 500 and over | 1 | 1983 | 8 | 0.000 |
Why?
|
| Nurseries, Hospital | 1 | 1983 | 4 | 0.000 |
Why?
|
| Maternal-Fetal Exchange | 1 | 1983 | 10 | 0.000 |
Why?
|
| Policy Making | 1 | 1983 | 15 | 0.000 |
Why?
|
| Breast Feeding | 1 | 1983 | 155 | 0.000 |
Why?
|